Patent application number | Description | Published |
20090098537 | Biomarker for Sensitivity to mTOR Inhibitor Therapy in Kidney Cancer - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells. | 04-16-2009 |
20090155787 | Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 06-18-2009 |
20100029676 | T315A AND F317I MUTATIONS OF BCR-ABL KINASE DOMAIN - The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins. | 02-04-2010 |
20100055687 | Mutations in the BCR-ABL tyrosine kinase associated with resistance to ST1-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 03-04-2010 |
20100248241 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 09-30-2010 |
20110045459 | Molecular determinants of EGFR kinase inhibitor response in glioblastoma - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregulated in pathologies such as cancer and to reagents and kits adapted for performing such methods. | 02-24-2011 |
20120021425 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 01-26-2012 |
20120282622 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 11-08-2012 |